Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.410
-0.020 (-1.40%)
At close: Dec 10, 2025, 4:00 PM EST
1.410
0.00 (-0.03%)
After-hours: Dec 10, 2025, 7:23 PM EST
Telomir Pharmaceuticals Employees
As of December 31, 2023, Telomir Pharmaceuticals had 9 total employees, including 1 full-time and 8 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,250,043
Market Cap
48.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TELO News
- 15 days ago - Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - Accesswire
- 19 days ago - Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Accesswire
- 4 weeks ago - Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line - Accesswire
- 6 weeks ago - Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo - Accesswire
- 7 weeks ago - Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth - Accesswire
- 2 months ago - Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer - Accesswire
- 2 months ago - Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug - Benzinga
- 2 months ago - Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - Accesswire